TGFB1 and neoplasm: LY2109761 (LY) is a novel selective TGF-β receptor type I/II inhibitor that completely inhibits TGF-β-induced SMAD2 phosphorylation and exhibits antitumor effects in various tumor models, such as glioblastoma [22], oral squamous cell carcinoma [23] and prostate cancer [24].